#SamediCuiCui Poke @khoyoulaa.bsky.social et @transvinylexpress.eurosky.social 🎨 : Rebecca Rebouché - Swan Tree (from her Modern Mythology series)

Thrilled to post thread re: new single-cell lineage of mouse embryo reconstructed w/ DNA Typewriter. One animal, zygote to late organogenesis (E13.5). Tree has 1,340,794 transcriptionally profiled, annotated tips (cells), 1,142,588 dated internal nodes, rooted at zygote 1/n

Global warming is already harming human health in countless ways. We can now add smoke-related deaths to the growing list. By David Wallace-Wells of the NYT. www.nytimes.com/2026/07/22/o...

Hopstem has received FDA IND clearance and Fast Track designation for its allogeneic #iPSCells-derived forebrain neural progenitors therapy in both hemorrhagic stroke and traumatic brain injury. Hopstem is a Chinese company (Hangzhou) also based in Houston. #StemCell #Stroke

Industry News and Analysis | FirstWord PHARMA

Stay updated with the latest news, insights, and analysis from FirstWord PHARMA. FirstWord PHARMA provides comprehensive coverage of key developments and trends.

firstwordpharma.com

“You will get the country you voted for. That country is one where we will no longer innovate. We will be less secure, less healthy, and less wealthy because some community of people who influence what this country is do not see the value of science” - Neil deGrasse Tyson — It’s already too late.

📣 SAVE THE DATE! The 8th FSSCR Meeting will be held in Paris from Tuesday 11 to Thursday 13 May 2027. As usual, our scientific committee is curating an exceptional lineup of prestigious speakers (to be announced soon) from some of the most renowned research centres. STAY TUNED. #FSSCR #StemCells

@kenaitx.bsky.social has completed enrollment in the Phase 1b/2a REPLACE™ trial of RNDP-001, an off-the-shelf allogeneic dopaminergic neuron replacement therapy derived from #iPSCells. Early efficacy data are now eagerly awaited. #CellTherapy buff.ly/XD3llbo

Kenai Therapeutics Announces Completion of Enrollment in Phase 1b/2a REPLACE™ Trial of RNDP-001 — Kenai Therapeutics

Kenai Therapeutics, a clinical-stage biotechnology company pioneering next generation approaches to cure neurological conditions, today announced the completion of enrollment for the REPLACE™ Phase…

kenaitx.com

Awesome #evolution tool shows when humans separated from other species: 1bn years fungi, 6m years chimpanzees. Source: buff.ly/2l0gV64

Tech companies treating cautionary tales from science fiction as product roadmaps is one of my least favorite things about this timeline.

An AI-generated small-molecule inhibitor treats fibrosis in vivo and in phase I clinical trials go.nature.com/3IvPOuI rdcu.be/d8EOQ

A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models - Nature Biotechnology

An AI-generated small-molecule inhibitor treats fibrosis in vivo and in phase I clinical trials.

go.nature.com

In June, genome-editing pioneer Sangamo Therapeutics filed for bankruptcy. A change of era for one of the field's early trailblazers. buff.ly/wgGhrdh

From cloning to gene-editing: the enduring legacy of Dolly the sheep. 30 years after. buff.ly/5REIgRz

From cloning to gene-editing: the enduring legacy of Dolly the sheep

Dolly’s brush with celebrity could hold lessons for current discussions about reproductive technologies.

nature.com

Encouraging early clinical data for #iPSC-derived #CART therapy in autoimmune disease. Off-the-shelf FT819 showed promising activity in systemic sclerosis patients, with no CRS, ICANS or GvHD reported. A potential step toward on-demand CAR-T. #CellTherapy #ISSCR2026

📢 Les inscriptions au Diplôme Universitaire « Thérapies Cellulaire & Génique – Médecine Régénératrice » de la Faculté de Médecine de Montpellier sont ouvertes! 📅 Formation intensive du 9 au 20 novembre 2026 💻 Accessible en présentiel ou en distanciel 😀 Inscriptions : buff.ly/5jebkp6

Cette animation est saisissante. Elle montre, en seulement quelques secondes, l'accélération spectaculaire de la fréquence des vagues de chaleur au cours des 126 dernières années en France. 1/3

The pace of AI progress is exponential. So is its capacity to create value. This argues against an AI bubble.

Dare Obasanjo@carnage4life.bsky.social · last mo.

The full SemiAnalysis article is below

Network-driven discovery of repurposable drugs targeting hallmarks of aging @nataging.nature.com @barabasi.bsky.social @northeasternu.bsky.social www.nature.com/articles/s43...

Intravesical mesothelin-based CAR T cells targeting MUC16 effectively control bladder cancer in preclinical models @jem.org @roswellpark.bsky.social @weillcornell.bsky.social rupress.org/jem/article/...

Exciting conference in Paris! 📅 21–22 September 2026 Cell plasticity in Development and Disease. #SFBD #FSSCR IT cell biology, reproduction, development and evolution

Exciting news for the stem cell community! 🚀 FDA IND clearance for an allogeneic #iPSC-derived dopaminergic progenitor cell therapy for Parkinson's disease, after a Chinese IND approval. Another important milestone toward global clinical translation of off-the-shelf iPSC therapies.

UniXell Biotechnology Secures FDA IND Clearance for UX-DA003, Achieving China-U.S. Dual Breakthrough in iPSC Parkinson's Therapy

/PRNewswire/ -- UniXell Biotechnology Co., Ltd. ("UniXell") has secured Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration...

buff.ly

This. (Les morts ont déjà commencé).

Le Tropeur@letropeur.eurosky.social · last mo.

Durant cette canicule, y a des gens qui vont perdre des parents, des enfants, des ami.e.s. Il est crucial de bien comprendre que ce ne sont pas des morts accidentelles. Des gens ont pris les décisions qui ont mené à cette canicule, en toute connaissance de cause.

Major milestone for cell therapy: satri-cel, a Claudin18.2-targeted autologous CAR-T, has been approved in China for advanced gastric/GEJ adenocarcinoma after ≥2 prior lines. It is the first approved CAR-T therapy for solid tumors. #CART

CARsgen Announces Approval of Satri-cel, the World's First CAR T-Cell Therapy Product for Solid Tumors

/PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that as...

buff.ly

“Do we really want to play dice with our planet?“ [’Termination shock’: trust our expert warnings on geoengineering’s planetary risks | Raymond Pierrehumbert, Julia Slingo, Michael Mann and Valerie Masson-Delmotte | The Guardian] www.theguardian.com/commentisfre...

‘Termination shock’: trust our expert warnings on geoengineering’s planetary risks | Raymond Pierrehumbert, Julia Slingo, Michael Mann and Valerie Masson-Delmotte

Do we really want to play dice with our planet?

theguardian.com

Silent giant nobody covers: the biggest AI story this year isnt a new model. Its that a handful of companies now own the compute, the data, and the talent. The race already has a finish line, and most of us were never in it. Who is actually checking that power?

Obama: "As algorithms keep feeding us a steady stream of distraction and outrage, as only the loudest most extreme voices get attention, fanning our prejudices, appealing to our basest most tribal instincts, it's tempting to give in to cynicism and even despair, to stop trying."

Meta is cutting 8,000 jobs while raising its Texas AI data center budget from $1.5B to over $10B. Read that twice. They're not trimming costs. They're swapping payroll for compute. This is the AI economy in one move. Are we ready for what it means?

Historic FDA approval brings first gene therapy for genetic deafness www.nature.com/articles/s41...

Historic FDA approval brings first gene therapy for genetic deafness - Nature Biotechnology

The first-of-its-kind genetic medicine treats a rare and profound otoferlin-related hearing loss, and will be made available by Regeneron for free in the United States.

nature.com

In vivo #CRISPR reaches a new milestone: in a first Phase III trial, a single intravenous infusion reduced hereditary angioedema attacks by 87% compared with placebo. Gene editing is moving from promise to reality. buff.ly/aRSVbbN

In vivo CRISPR therapy successfully reduces hereditary angioedema attacks in first Phase III trial

Researchers from Amsterdam UMC, in collaboration with other hospitals, have successfully completed the first Phase III study of an in vivo CRISPR therapy. In this large-scale, double-blind trial, 80…

medicalxpress.com

📢 Les inscriptions au Diplôme Universitaire « Thérapies Cellulaire & Génique – Médecine Régénératrice » de la Faculté de Médecine de Montpellier sont ouvertes! 📅 Formation intensive du 9 au 20 novembre 2026 💻 Accessible en présentiel ou en distanciel 😀 Inscriptions : buff.ly/5jebkp6

« La démocratie passe par la lecture ». C'est « notre plus puissant outil de réflexion analytique et stratégique. Sans elle, nous sommes mal équipés pour contrer les simplifications populistes, les théories du complot et la désinformation, ce qui nous rend vulnérables à la manipulation ».

Le déclin de la lecture face à l’avénement des écrans marque-t-il la fin de l’ère démocratique ?

Si les angoisses d’affaiblissement des facultés de l’esprit face aux nouvelles technologies ne datent pas d’hier, la révolution numérique et l’intelligence artificielle laissent entrevoir la fin de la...

lemonde.fr